New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
11:07 EDTMYGNMyriad Genetics price target raised to $42 from $34 at Piper Jaffray
Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:09 EDTMYGNMyriad Genetics presents myChoice HRD companion diagnostic test data at ASCO
Subscribe for More Information
07:06 EDTMYGNMyriad Genetics presents myRisk Hereditary Cancer data at ASCO
Myriad Genetics announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting. The myRisk Hereditary Cancer test assesses 25 genes for mutations associated with eight hereditary cancers. Finding deleterious mutations in these genes can help patients with cancer receive appropriate medical care and reduce the risk of second cancers, while patients without cancer can take steps in consultation with their healthcare provider to lower their risk of developing cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use